The World Health Organization (WHO) applauds the Government of South Africa and President Cyril Ramaphosa for the launch of the national rollout of lenacapavir, a groundbreaking long-acting HIV prevention injection that marks a major milestone in the country's efforts to reduce new HIV infections and move closer to ending HIV. Launched in Secunda, Mpumalanga province, the introduction of the twice-yearly injectable pre-exposure prophylaxis (PrEP) option demonstrates South Africa's continued commitment to expanding access to effective, people-centred prevention options.
Dr Tedros Adhanom Ghebreyesus, WHO Director-General, in his video address, congratulated the Government and people of South Africa on the rollout of the national lenacapavir programme:
"South Africa is among the first countries to move from policy to implementation – receiving early supply, updating its essential medicines list, and preparing health systems for rollout," he said. "It demonstrates what is possible when governments, communities and partners work together with clear purpose. Today marks an important milestone in South Africa's long fight against HIV."
South Africa has long been a global leader in the HIV response, driven by strong political commitment, scientific excellence, and community partnerships. The rollout of lenacapavir builds on decades of progress and reflects the country's determination to ensure that new prevention technologies reach those who need them most. By introducing this highly effective prevention tool into public health programmes, South Africa joins the other early adopter countries seeking to accelerate progress towards ending HIV and reducing health inequities.
"South Africa's rollout of lenacapavir demonstrates the country's continued commitment to expanding access to innovative HIV prevention tools," said Dr Tereza Kasaeva, Director of WHO's Department for HIV, TB, Hepatitis and STIs. "WHO remains committed to supporting South Africa's efforts to expand access to HIV prevention and end HIV by 2030".
